Royal Bank of Canada Lowers Hookipa Pharma (NASDAQ:HOOK) Price Target to $48.00

Hookipa Pharma (NASDAQ:HOOK) had its target price decreased by Royal Bank of Canada from $50.00 to $48.00 in a note issued to investors on Friday,Briefing.com Automated Import reports. The firm currently has an “outperform” rating on the stock.

Separately, JMP Securities lifted their target price on Hookipa Pharma from $23.00 to $24.00 and gave the stock a “market outperform” rating in a research note on Friday, August 9th.

Hookipa Pharma Price Performance

Shares of HOOK stock traded down $0.14 on Friday, reaching $3.00. 26,663 shares of the company were exchanged, compared to its average volume of 56,879. Hookipa Pharma has a one year low of $2.95 and a one year high of $11.30. The company has a 50-day moving average of $4.16 and a 200-day moving average of $5.80. The company has a market cap of $36.18 million, a price-to-earnings ratio of -0.72 and a beta of 0.84.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC boosted its position in Hookipa Pharma by 38.4% in the second quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock worth $179,000 after purchasing an additional 83,800 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Hookipa Pharma by 12.3% in the second quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock worth $586,000 after acquiring an additional 108,844 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Hookipa Pharma during the 1st quarter valued at approximately $31,000. Institutional investors own 63.88% of the company’s stock.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.